Document is current
Any future updates will be listed below
-
Authors
Rosa, Márta Erzsébet
Juhász, Zoltán
Pásztor Mészáros, Gabriella
Magyar, Gabriella
Harsányi, Judit
Szatmári, Balázs
Hujber, Zoltán
Szabó, Máté
Kapás, Margit
-
Funding
Funding for this research was provided by:
Gedeon Richter
- License Information
-
More Information
Article History
Received: 3 October 2024
Accepted: 12 November 2024
First Online: 19 December 2024
Declarations
:
: Marta Erzsebet Rosa, Zoltan Juhasz, Gabriella Pasztor Meszaros, Gabriella Magyar, Judit Harsanyi, Balazs Szatmari, Zoltan Hujber, Mate Szabo and Margit Kapas are employees of Gedeon Richter Plc., the originator of cariprazine, or were full-time employees at the time the study was performed.
: The study was conducted according to Declaration of Helsinki standards and was approved by the following committees: Republic of Bulgaria Ministry of Health Ethics Committee for Clinical Trials, 8, Damyan Gruev Str. 1303, Sofia, Bulgaria; Ethics Committee at MNCE “Odesa Regional Medical Center of Mental Health” of the Odessa Regional Council; 9, Ac. Vorobjeva st., Odesa, 65006; Ethics Committee of CI “Dnipropetrovsk Regional Clinical Hospital n.a. I. I. Mechnikov, 14, Soborna quare Dnipro, 49005; Ethics Committee at Municipal Institution “Vinnytsya Regional Psychoneurological Hospital n.a. Acad. O.I. Yushchenko” 109, M.I. Pyrohova st., Vinnytsia, 21005; Communal Institution of Lviv Regional Council “Lviv Regional Clinical Psychiatric Hospital” (Ci Lrc Lrcph) Ethics Committee 95 Kulparkirivska str., Lviv city, 79021. All subjects signed the informed consent form before any study procedures were performed.
